Wikipedia:WikiProject Chemicals/Chembox validation/VerifiedDataSandbox and Acitretin: Difference between pages
Appearance
(Difference between pages)
Content deleted Content added
Saving copy of the {{drugbox}} taken from revid 458660569 of page Acitretin for the Chem/Drugbox validation project (updated: 'DrugBank'). |
m v2.05b - Bot T20 CW#61 - Fix errors for CW project (Reference before punctuation) |
||
Line 1: | Line 1: | ||
{{Short description|Chemical compound}} |
|||
{{ambox | text = This page contains a copy of the infobox ({{tl|drugbox}}) taken from revid [{{fullurl:Acitretin|oldid=458660569}} 458660569] of page [[Acitretin]] with values updated to verified values.}} |
|||
{{More medical citations needed|date=December 2023}} |
|||
{{Use dmy dates|date=February 2024}} |
|||
{{Drugbox |
{{Drugbox |
||
⚫ | |||
| Verifiedfields = changed |
|||
| image = Acitretin2DACS.svg |
|||
⚫ | |||
| alt = |
|||
⚫ | |||
| |
| image2 = Acitretin-from-xtal-3D-bs-17.png |
||
| alt2 = |
|||
<!--Clinical data--> |
<!--Clinical data--> |
||
| tradename = Soriatane |
| tradename = Soriatane, Neotigason |
||
| Drugs.com = {{drugs.com|monograph|acitretin}} |
| Drugs.com = {{drugs.com|monograph|acitretin}} |
||
| MedlinePlus = a601010 |
| MedlinePlus = a601010 |
||
| pregnancy_AU = |
| pregnancy_AU = X |
||
⚫ | |||
| pregnancy_US = <!-- A / B / C / D / X --> |
|||
⚫ | |||
| pregnancy_category = X |
|||
⚫ | |||
| legal_AU = <!-- Unscheduled / S2 / S4 / S8 --> |
|||
⚫ | |||
| legal_UK = <!-- GSL / P / POM / CD --> |
|||
⚫ | |||
| legal_AU = S4 |
|||
| legal_AU_comment = <ref name="AU Neotigason">[https://www.tga.gov.au/resources/artg/52455 NEOTIGASON acitretin 10mg capsule blister pack (52455)] Australian Department of Health and Aged Care</ref> |
|||
| legal_BR = C2 |
|||
| legal_BR_comment = <ref>{{Cite web |author=Anvisa |author-link=Brazilian Health Regulatory Agency |date=2023-03-31 |title=RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial |trans-title=Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control|url=https://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-784-de-31-de-marco-de-2023-474904992 |url-status=live |archive-url=https://web.archive.org/web/20230803143925/https://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-784-de-31-de-marco-de-2023-474904992 |archive-date=2023-08-03 |access-date=2023-08-15 |publisher=[[Diário Oficial da União]] |language=pt-BR |publication-date=2023-04-04}}</ref> |
|||
| legal_CA = Rx-only |
|||
| legal_UK = POM |
|||
⚫ | |||
| legal_US_comment = <ref name="Soriatane FDA label">{{cite web | title=Soriatane (acitretin) Capsules | website=dailymed.nlm.nih.gov | url=https://dailymed.nlm.nih.gov/dailymed/archives/fdaDrugInfo.cfm?archiveid=709670 | access-date=30 December 2023}}</ref> |
|||
| legal_status = |
| legal_status = |
||
⚫ | |||
<!--Pharmacokinetic data--> |
<!--Pharmacokinetic data--> |
||
| bioavailability = 60% |
| bioavailability = 60% |
||
| protein_bound = 99% |
| protein_bound = >99.9% |
||
| metabolism = |
| metabolism = Liver |
||
| elimination_half-life = 49 hours |
| elimination_half-life = 49 hours |
||
| excretion = |
| excretion = Faeces & urine |
||
<!--Identifiers--> |
<!--Identifiers--> |
||
| IUPHAR_ligand = 7598 |
|||
| CASNo_Ref = {{cascite|correct|CAS}} |
|||
| CAS_number_Ref = {{cascite|correct|??}} |
| CAS_number_Ref = {{cascite|correct|??}} |
||
| CAS_number = 55079-83-9 |
| CAS_number = 55079-83-9 |
||
⚫ | |||
⚫ | |||
⚫ | |||
| PubChem = 5284513 |
| PubChem = 5284513 |
||
| DrugBank_Ref = {{drugbankcite| |
| DrugBank_Ref = {{drugbankcite|correct|drugbank}} |
||
| DrugBank = DB00459 |
| DrugBank = DB00459 |
||
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}} |
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}} |
||
Line 48: | Line 55: | ||
<!--Chemical data--> |
<!--Chemical data--> |
||
⚫ | |||
| C=21 | H=26 | O=3 |
| C=21 | H=26 | O=3 |
||
| molecular_weight = 326.429 g/mol |
|||
| smiles = O=C(O)\C=C(\C=C\C=C(\C=C\c1c(cc(OC)c(c1C)C)C)C)C |
| smiles = O=C(O)\C=C(\C=C\C=C(\C=C\c1c(cc(OC)c(c1C)C)C)C)C |
||
| InChI = 1/C21H26O3/c1-14(8-7-9-15(2)12-21(22)23)10-11-19-16(3)13-20(24-6)18(5)17(19)4/h7-13H,1-6H3,(H,22,23)/b9-7+,11-10+,14-8+,15-12+ |
|||
| InChIKey = IHUNBGSDBOWDMA-AQFIFDHZBN |
|||
| StdInChI_Ref = {{stdinchicite|correct|chemspider}} |
| StdInChI_Ref = {{stdinchicite|correct|chemspider}} |
||
| StdInChI = 1S/C21H26O3/c1-14(8-7-9-15(2)12-21(22)23)10-11-19-16(3)13-20(24-6)18(5)17(19)4/h7-13H,1-6H3,(H,22,23)/b9-7+,11-10+,14-8+,15-12+ |
| StdInChI = 1S/C21H26O3/c1-14(8-7-9-15(2)12-21(22)23)10-11-19-16(3)13-20(24-6)18(5)17(19)4/h7-13H,1-6H3,(H,22,23)/b9-7+,11-10+,14-8+,15-12+ |
||
Line 58: | Line 63: | ||
| StdInChIKey = IHUNBGSDBOWDMA-AQFIFDHZSA-N |
| StdInChIKey = IHUNBGSDBOWDMA-AQFIFDHZSA-N |
||
}} |
}} |
||
'''Acitretin''', sold under the brand names '''Neotigason'''<ref name="AU Neotigason" /> and '''Soriatane''',<ref name=":0" /> is a second-generation [[retinoid]]. It is taken orally, and is typically used for [[psoriasis]].<ref name="Zito_2021">{{cite book | vauthors = Zito PM, Mazzoni T | date = January 2021 | chapter = Acitretin | chapter-url = https://www.ncbi.nlm.nih.gov/books/NBK519571 | title = StatPearls | pmid = 30137855 | location = Treasure Island (FL) | publisher = StatPearls Publishing }}</ref> |
|||
Acitretin is an oral retinoid used in the treatment of severe resistant psoriasis. Because of the potential for problems and severe side effects it is generally used in only very severe cases of psoriasis that have been unresponsive to other treatments. It binds to nuclear receptors that regulates gene transcription. They induce [[keratinocyte]] differentiation and reduce epidermal hyperplasia, leading to the slowing of cell reproduction. Acitretin is readily absorbed and widely distributed after oral administration. A therapeutic effect occurs after two to four weeks or longer. |
|||
Patients who have received the medication are advised against giving blood for at least three years due to the risk of birth defects.<ref>AABB Technical Manual, American Association of Blood Banks</ref> |
|||
==Adverse effects== |
|||
Acitretin is highly [[teratogenic]] and noted for the possibility of severe birth defects. It should not be used by pregnant women or women planning to get pregnant within 3 years following the use of acitretin. Sexually active women of childbearing age who use acitretin should also use at least two forms of birth control concurrently. Men and women who use it should not donate blood for three years after using it, because of the possibility that the blood might be used in a pregnant patient and cause birth defects. In addition, it may cause nausea, headache, itching, dry, red or flaky skin, dry or red eyes, dry or chapped lips, swollen lips, dry mouth, thirst, [[cystic acne]] or hair loss.<ref>{{cite web|url=http://www.webmd.com/drugs/drug-4719-soriatane+oral.aspx?drugid=4719&drugname=soriatane+oral|title=Soriatane|work=[[WebMD]]|access-date=15 August 2015}}</ref><ref name=":0">{{cite web|url=https://www.drugs.com/sfx/soriatane-side-effects.html|title=Soriatane Side Effects|work=[[Drugs.com]]|access-date=15 August 2015}}</ref><ref>{{cite web|url=http://www.rxlist.com/soriatane-drug.htm|title=Soriatane (Acitretin) Drug Information: Description, User Reviews, Drug Side Effects, Interactions - Prescribing Information at RxList|work=[[RxList]]|access-date=15 August 2015|archive-url=https://web.archive.org/web/20131202230458/http://www.rxlist.com/soriatane-drug.htm|archive-date=2 December 2013|url-status=dead}}</ref> |
|||
== Pharmacokinetics == |
|||
It is a metabolite of [[etretinate]], which was used prior to the introduction of acitretin. Etretinate was discontinued because it had a narrow [[therapeutic index]] as well as a long [[elimination half-life]] (''t''<sub>1/2</sub> = 120 days), making dosing difficult. In contrast, acitretin's half-life is approximately 2 days. However, because acitretin can be reverse [[Metabolism|metabolised]] into [[etretinate]] which has an extremely long half-life, women must avoid becoming pregnant for at least three years<ref>{{cite web|url=http://www.soriatane.com/#isi-content|title=Important Safety Information for SORIATANE|work=soriatane.com|access-date=31 October 2015}} </ref> after discontinuing acitretin. Therefore, acitretin is generally not recommended for women of child-bearing age with a risk of becoming pregnant. |
|||
==References== |
|||
{{Reflist}} |
|||
{{Antipsoriatics}} |
|||
{{Retinoid receptor modulators}} |
|||
{{GlaxoSmithKline}} |
|||
{{Portal bar | Medicine}} |
|||
[[Category:Drugs developed by GSK plc]] |
|||
[[Category:Retinoids]] |
|||
[[Category:Phenol ethers]] |
|||
[[Category:Enones]] |
|||
[[Category:Hepatotoxins]] |
|||
[[Category:Drugs developed by Hoffmann-La Roche]] |